International Journal of Hematology and Oncology 2022, Vol 32, Num 3 (Special Issue) Page(s): 004-009
Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure


Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, TURKEY

Keywords: Chronic myeloid leukemia, Targeted therapy, Imatinib, Dasatinib, Nilotinib
Invention of imatinib was a great step for much more successful clinical management of chronic myeloid leukemia (CML). Now, two other tyrosine kinase inhibitors (TKIs) are available both for first-line and later treatments of CML. In Turkey, currently 2nd line TKIs are indicated only for imatinib failure. This review will evaluate indications for changing imatinib with dasatinib or nilotinib, success of the 2nd line agents in the second-line treatment and some important properties of these agents.